[CLSTR]
API
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [HEALTH]

9 clusters · 20 sources · 37 days · First seen · Last updated

STAREE trial and evolving cholesterol treatments

Overview

The STAREE trial, a large-scale clinical study involving nearly 10,000 participants from Australian general practices, has demonstrated that daily atorvastatin significantly reduces the risk of major cardiovascular events in healthy adults aged 70 and older. Findings published in the New England Journal of Medicine indicate a 30 per cent reduction in the risk of cardiovascular death, nonfatal myocardial infarction, stroke, and coronary revascularization among participants with no prior history of cardiovascular disease, diabetes, or dementia. While the medication successfully lowered cardiovascular risks, researchers noted that it did not significantly improve mortality, dementia, or disability-free survival.

Newer details from the study, presented at the European Society of Cardiology congress, specify that the research led by Professor Sophia Zoungas of Monash University involved 9,971 participants with a median follow-up of 5.9 years. While the 30 per cent reduction in serious cardiovascular events was significant, the study noted that participants receiving 40 mg of atorvastatin experienced higher rates of muscle, liver, and diabetes-related side effects compared to the control group. However, the overall rate of serious adverse events remained equal between both groups at 2.7 per cent.

Recent research has further nuanced the approach to preventative care for the elderly. A study published in The Lancet Healthy Longevity suggests that adults aged 75 and older may safely discontinue primary prevention statin therapy if they have no history of heart attack or stroke. Additionally, research published in Nature Communications suggests that atorvastatin may interfere with the RyR1 protein, potentially explaining reported muscle pain.

Entities

European Society of Cardiology · New England Journal of Medicine · Monash University · University of British Columbia · Mark Nelson

Timeline

  1. [HEALTH] 2 sources
    STAREE study: Atorvastatin reduces major heart events in elderly by 30%

    The STAREE study found that 40 mg of daily atorvastatin reduces serious cardiovascular events by 30% in adults over 70 without prior disease, though it had no impact on mortality or dementia.

  2. [HEALTH] 2 sources
    Statins: New research explores muscle pain mechanisms and side effect risks

    Researchers have identified a potential mechanism for statin-induced muscle pain involving calcium leaks in muscle cells, while a large study suggests many other reported side effects lack significant links to.

  3. [HEALTH] 2 sources
    Medical studies suggest new preventative health findings for elderly populations

    New studies suggest seniors may safely stop statin therapy after age 75 without increased mortality risk, and that the herpes-zoster vaccine may reduce dementia risk in older populations.

  4. [HEALTH] 2 sources
    Medical research advances in cardiovascular health and biological aging

    New medical studies show atorvastatin reduces cardiovascular risk by 30% in seniors, CRISPR therapy may significantly lower cholesterol, and Rentosertib shows potential in slowing biological aging.

  5. [HEALTH] 2 sources
    Medical studies clarify benefits of cholesterol treatments for seniors and high-risk patients

    Medical studies confirm that statins reduce cardiovascular risks in adults over 70 by 30%, while PCSK9 inhibitors offer an alternative for managing severe LDL cholesterol levels.

  6. [HEALTH] 2 sources
    Statins: New insights into muscle pain causes and cardiovascular benefits

    New research explores why statins cause muscle pain via the RyR1 protein, while a major trial shows the drugs reduce cardiovascular events in adults over 70 by 30% despite no impact on disability-free survival.

  7. [HEALTH] 4 sources
    Monash University study finds statins reduce heart risk in seniors

    A decade-long Monash University study found that daily statins reduce the risk of major cardiovascular events by 30% in healthy adults over age 70.

  8. [HEALTH] 2 sources
    STAREE trial finds atorvastatin reduces cardiovascular events in older adults

    The STAREE trial found that atorvastatin reduces major cardiovascular events by 30% in adults aged 70+ without prior disease, though it did not significantly improve disability-free survival.

  9. [HEALTH] 2 sources
    Monash University study finds statins reduce heart attack risk in adults over 70

    A Monash University study found that statins reduce heart attack and stroke risk by 30 per cent in healthy adults over 70, providing new evidence for preventative care in older populations.

Sources

ad-hoc-news.de · consultantlive.com · doctorulzilei.ro · elbalad.news · em.com.br · farmacoecura.it · flux24.ro · independent.co.uk · knowridge.com · lomazoma.com · medicaldialogues.in · microbiologiaitalia.it · optimistdaily.com · sawt-alasima.net · theage.com.au · theguardian.com · time.news · tribunademinas.com.br · womensweekly.com.au · ye-voice.com

This summary has been updated 8 times: see revision history